NCT06946160View on ClinicalTrials.gov

A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions
Glabellar LinesGlabellar Frown Lines
Interventions
DRUG

Abobotulinumtoxin A (Espad Pharmed Darou Co.)

Vial of Abobotulinumtoxin A (produced by Espad Pharmed Darou Co.), administered via deep intramuscular injection

DRUG

Abobotulinumtoxin A (Ipsen Co.)

Vial of AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.), administered via deep intramuscular injection

Trial Locations (1)

Unknown

Center for Research and Training in Skin Diseases And Leprosy, Tehran

All Listed Sponsors
lead

Espad Pharmed

INDUSTRY

NCT06946160 - A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter